OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Grace Stutzmann

3 Projects | 1 Researchers | $528,048 Invested

2015

RFUMS/Chicago Medical School

Grace Stutzmann, PhD

Drug development and optimization of compounds stabilizing ryanodine calcium channels for AD

  • Funding Amount: $257,942
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Calcium Regulation
  • Status: Closed

2013

Rosalind Franklin University of Medicine and Science

Grace Stutzmann, PhD

Stabilizing ryanodine calcium channels as a novel drug development strategy for Alzheimer's disease therapeutics

  • Funding Amount: $170,106
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed

2010

Rosalind Franklin University of Medicine and Science

Grace Stutzmann, PhD

Targeting neuronal calcium dysregulation to halt AD pathogenesis

  • Funding Amount: $100,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed